How Wearables Help Manage Chronic Diseases Like Hypertension
- Deblina Chattopadhyay
- 6 hours ago
- 13 min read
Wearable devices are emerging as powerful tools for hypertension management by enabling continuous, non-invasive blood pressure monitoring using technologies like PPG, ECG, and Pulse Transit Time (PTT). While wearables cannot yet replace clinical-grade blood pressure cuffs for diagnosis, they are valuable for tracking trends, detecting masked hypertension, monitoring blood pressure variability, and supporting long-term cardiovascular care.
What Are Wearable Devices in Chronic Disease Management?
Non-interfering wearable devices such as smart rings, wristbands or chest patches can prove to be better continuous monitors if sufficiently validated and could offer across weeks or months worth of the same information at a fraction of the cost and hurdle than that of a single day.
How Do Wearables Measure Blood Pressure?
Traditional cuffs use oscillometry to measure blood pressure, whereas wearable devices often rely on other methods:
Pulse Transit Time (PTT)
One of the most widely researched methods is Pulse Transit Time as it measures the time taken for a pulse to travel between two points in the cardiovascular system. It is typically detected using ECG and PPG. Shorter transit time in an individual generally indicates higher blood pressure, whereas lower blood pressure levels are when the transit time is longer. PTT varies and is affected by different physiological factors such as arterial stiffness, which makes it challenging to estimate accuracy.
Studies have shown that PTT-based blood pressure is not completely reliable and might only moderately correlate with the reference measurements, and in some cases might overestimate the nighttime blood pressure.¹
Photoplethysmography (PPG)
It is common among wearables to use optical sensors to measure the changes in blood volume because of variations in microvascular tissue. PPG signals can be analyzed with edge-AI algorithms or machine learning models to estimate blood pressure trends. These optical sensors are used in wearable devices for heart rate monitoring, oxygen saturation and pulse wave analysis.
Electrocardiography (ECG)
Some advanced wearable devices such as Orbyt ring, Apple Watch, Samsung Watch, Fitbit, etc. leverage ECG signals as a part of vital signs monitoring. ECG provides a more precise timing of cardiac electrical activity, particularly the R-peak which marks the ventricular contraction.
In wearables, ECG can be used for the following purposes:
To improve timing accuracy in Pulse Transit Time calculations
To enable Pulse Arrival Time measurements when combined with PPG
Provide additional cardiovascular features such as Heart Rate Variability (HRV) that can enhance blood pressure models.
Emerging studies also explore ECG morphology with AI models to estimate blood pressure trends in an individual.
The sensor-fusion approach of ECG, PPG and contextual data is increasingly seen as a promising research for improving the accuracy in cuffless and continuous blood pressure level monitoring.
Inflated Cuff Oscillometry
Some wearable devices in the form of wristbands have also incorporated miniature inflated cuffs. These wearables function very similarly to the traditional cuff-based monitoring.
Validation studies have shown that few wrist-worn oscillometric devices can meet the established medical setting accuracy standards when tested against mercury sphygmomanometers.²
How Accurate Are Wearable Blood Pressure Monitors? What The Evidence Says?
Accuracy will always be the most important and maybe the most controversial parameter in wearable blood pressure monitoring devices. This is why we can assess the accuracy of blood pressure devices against international validation standards.
One of the widely referenced standards across the globe is the AAMI/ESH/ISO universal validation framework, which is a joint protocol from the the Europe Society of Hypertension, Association of Advancement of Medical Instrumentation and the International Organization for Standardization. This validation framework sets strict accuracy standards for devices measuring blood pressure. To pass, a device's readings must be very close to the true values: on average, the error should be no more than 5 mmHg, and most readings (as measured by standard deviation) should be within 8 mmHg of the actual value.³
What Studies show about Blood Pressure Accuracy in Wearables?
A systematic review and meta-analysis published in ScienceDirect in 2025 revealed that evaluating cuffless wearable devices for BP monitoring against the conventional method of 24-hour ABPM shows comparable accuracy for daytime blood pressure levels. The study also revealed that the mean differences for the systolic and diastolic BP measurements were within the acceptable range of -0.99 mmHg.
However, another critical finding revealed that the current wearable technology for cuffless BP monitoring is not yet reliable for nocturnal assessments. This is a significant limitation knowing the importance of nocturnal blood pressure.⁴
In around 245 publications across 2010-2014, it was found that the method most widely used for BP measurements in wearables was done with a combination of PPG with PTT as the core parameters and additionally machine learning being incorporated in it. Accuracy in these wearables was found to be more for diastolic than systolic BP, as systolic levels showed a greater variability. Systolic BP is the primary driver for risks in cardiovascular activity and the main target for therapy within hypertension guidelines, thus making cuffless wearables, not the most reliable yet for monitoring BP levels, but cautiously optimistic.⁵
Wearables In Hypertension Care - Use Cases That Work Today
Even with the given accuracy limitations of cuffless wearable BP monitoring devices, there are specific evidence-supported data, where genuine clinical values are provided:
Screening and detection of hypertension in undiagnosed populations
Detecting masked hypertension and out of clinic BP elevation
Blood pressure variability monitoring and response to triggers
Long term treatment monitoring and medical response
Nocturnal BP monitoring as a supplement to ABPM
Remote patient monitoring and telehealth integration
Where Wearables Fall Short For Hypertension Management
After carefully acknowledging the genuine limitations of wearable technology for BP monitoring, we can say the foundation of their usefulness lies in the responsible use of the said devices and not inadvertently causing harm.
As discussed earlier, comparing wearable cuffless devices to conventional ABPM showed that daytime accuracy was more acceptable than the nighttime measurement of blood pressure which was unreliable overall. The particular challenge is in sleep related movement artifacts like physiological changes in arterial tone, say through wrist position movement.
Most cuffless blood pressure monitors need to be set up by comparing them to a standard cuff reading, and sometimes they need to be adjusted again later. But this setup process can be tricky, and people might not do it correctly on their own.
PPG sensor based devices are sensitive to several factors like skin colour, melanin content, motion artifacts during exercising, peripheral vascular disease, sensor contract variation and cold extremities reducing peripheral perfusion. These factors bring down the accuracy of data collected by wearables. Also, not enough studies have been conducted in populations that might need the device the most - like older adults, those with established hypertension conditions, artificial stiffness or with irregular rhythms.
Wearables collect physiological data from an individual, which raises questions about the security of collected health data. This intimate information, often stored in the cloud via third-party services, could have insurance implications, particularly since regulatory frameworks haven't fully addressed cybersecurity risks
Most wearable brands market themselves as wellness devices instead of clinical grade ones and thus face lower regulatory scrutiny than that of medical grade cuffed sphygmomanometers. This creates a market where the majority of available devices are neither clinically validated nor meaningfully regulated for accuracy. A JAMA analysis found that the majority of BP measuring devices sold globally, including the large majority available online, are unvalidated against accepted accuracy standards. The STRIDE BP international initiative has formally validated only approximately 432 devices from over 4,000 available on the market. This means a patient purchasing a wearable 'blood pressure smartwatch' from an online marketplace is overwhelmingly likely to be buying an unvalidated device with no proven clinical accuracy.⁶
The most important limitation of wearable BP monitoring devices are that they are not validated for diagnosis or for treatment decisions. Current hypertension guidelines from the American Heart Association and American College of Cardiology (2025), European Society of Cardiology (2024) and the European Society of Hypertension (2023), all claim that the cuffless method of BP monitoring by devices should not be used for diagnosis of hypertension or for guiding antihypertensive treatment decisions. However, these regulatory and clinical observations are based on the current evidence base and not simply technological pessimism.⁷
Heart Rate And Heart Rate Variability In Hypertension Management
Wearables are more reliable for tracking heart rate and heart rate variability, thanks to mature and validated algorithms. This makes them clinically useful for monitoring hypertension, though they can't replace actual blood pressure measurements.
What is HRV and why does it matter in Hypertension?
Heart rate variability is the variation in time between consecutive heartbeats, typically quantified as the root mean square of successive differences (RMSSD). It reflects the balance between sympathetic (activating) and parasympathetic (calming) branches of the autonomic nervous system. A higher resting HRV generally indicates healthy autonomic tone and cardiovascular resilience and a chronically low HRV indicates sympathetic dominance, which is a significant cardiovascular risk marker.
The connection between HRV and hypertension is well-established. In a long-term study of more than 10,000 individuals, those with a low HRV at baseline had significantly elevated risk of developing hypertension over 9 years of follow-up. This suggested that reduced autonomic function precedes the development of clinical hypertension. Research consistently shows that patients with hypertension have significantly lower SDNN and RMSSD values (both standard HRV metrics) compared to normotensive individuals, reflecting increased sympathetic nervous activity.⁸
How HRV complements but never replaces BP monitoring
Consumer wearables measure HRV using PPG sensors during sleep, capturing pulse-to-pulse intervals as a surrogate for beat-to-beat RR intervals from an ECG. In the context of hypertension, HRV data from wearables provides several clinically useful dimensions that BP readings alone do not:
Autonomic stress context: A low HRV reading on a day when BP appears controlled may signal underlying autonomic dysregulation that puts the patient at elevated cardiovascular risk.
Stress response tracking: Chronic work stress, sleep deprivation, and psychological burden consistently reduce HRV. Wearable HRV tracking can help identify periods of high physiological stress that are likely to drive BP elevation, enabling proactive lifestyle adjustment.
Treatment response: Some antihypertensive drugs, particularly beta-blockers, have direct effects on HRV. Tracking HRV alongside BP can provide additional evidence of treatment response.
Sleep quality linkage: Poor sleep quality reduces HRV and is independently associated with higher nocturnal and morning BP. Wearables that track both HRV and sleep architecture can help connect these variables.
The critical caveat is that HRV is not a blood pressure measurement and cannot substitute for one. A patient with excellent HRV can have severely elevated BP and a patient with impaired HRV may have well-controlled clinic readings. HRV is a complementary biomarker that adds cardiovascular context to BP data and not a replacement for measuring BP itself.⁹
Can A Wearable Replace A Blood Pressure Cuff?
To be blunt about it, in most cases a wearable should not replace a medical device. So no it cannot, at least not yet. Cuff based measurement still remains the clinical standard for diagnosing hypertension. Wearables should be currently viewed as complementary tools rather than replacement.
Wearables would be best used for the following:
Continuous monitoring
Detecting trends
Supporting lifestyle changes
Screening for potential issues
When abnormal trends are detected in an individual, confirmation with validated cuff based monitoring is recommended.
Clinical Integration - How Clinicians Can Use Wearable Data Responsibly
As wearables enter the clinical setting more frequently, a principled framework for its use is needed. The following reflects current best practice based on the 2025 guidelines:
What Wearables can Appropriately Inform
Triage and screening of patients like notification or pattern of elevated readings suggesting a clinical follow-up with a validated cuff measurement.
Pattern recognition post interpretation of BP pattern across time rather than individual data points.
Masked hypertension detection after noticing consistent elevated values in BP in a patient with contradicting clinical readings that may prompt referral for a 24 hour ABPM.
Treatment monitoring can be done when BP trends are monitored over several weeks and can prompt a clinical review for say dose adjustment or further investigation, as a supplement to clinical visits.
What Clinicians should not use Wearables for
Initiate or modify antihypertensive medications based solely on wearable BP readings.
Diagnose hypertension from wearable data without confirmation by a validated cuff device.
Accept wearable data uncritically without knowing whether the device is validated and whether calibration has been maintained.
Ignore wearable data that the patient presents as it may contain clinically useful signals even if it cannot be used diagnostically.
Practical Workflow for Integration of Wearables
The Japanese Society of Hypertension (JSH2025) guidelines and the broader 'digital hypertension' framework mention a practical model where wearable and digital BP data are most useful when integrated into a structured care framework. This includes validated device confirmation, clinician review of trends rather than individual data points. This should be aided with an adjacent clear protocol for when digital data triggers clinical action. The physician's clinical judgement remains crucial and digital data should support it, not replace it.¹⁰
What To Look For When Choosing A Wearable For Hypertension Support
Not all wearables are suitable for blood pressure monitoring and one must evaluate the following in a device to consider:
Medical grade: Confirm whether the device has been validated under recognized standards.
Measurement method: PPG, PTT, oscillometric cuff or a combination of them/ a hybrid method.
Calibration requirements: To establish how often the device needs to be calibrated by the user and if any professional help is needed in the process.
Data accessibility and security: The ability to share the data with clinicians and the privacy policy of the device and the data it collects and the said data storage security.
Regulatory approval: Understand whether the wearable is approved by established regulatory bodies such as FDA, CE or others.
The Future of Blood Pressure Monitoring: Cuffless Devices and Wearables
Emerging Technologies
Several new technologies, especially sensor modalities have been in development. Some wearable devices use miniaturised ultrasound probes which directly measure the motion of the arterial wall and compute blood pressure levels from pulse waveform. This offers a more physiologically direct measurement that does not require optical signals or arterial stiffness assumptions.
Applanation tonometry which is applying controlled contact pressure over an artery with the purpose of flattening the wall is being used in research grade wearable devices.
Another new technology which is the Bioelectrical Impedance Analysis (BIA) as incorporated into the Samsung Galaxy Watch 6 can complement BP monitoring by providing body composition data.
The Convergence of Accuracy and Practicality
The direction in which wearable BP monitoring is heading is clearly towards higher accuracy and better validation, thus better clinical applicability. The key scientific challenges are calibration drift, systolic BP estimation and variability, skin tone sensitivity and nocturnal accuracy, which are all active areas of research . The FDA had issued a draft guidance on cuffless BP device validation (2024), the Nature Reviews Bioengineering has recently published a major framework for multi-standard validation of cuffless devices in 2026, which highly suggests the maturing process of regulatory and scientific infrastructure for wearable devices.
The Gold Standard Goal: Beat by Beat Continuous Monitoring
The ultimate goal mentioned in hypertension monitoring guidelines is to have continuous capturing of data, like every heartbeat’s pressure through a device that is comfortable enough to be worn indefinitely. This will help in detecting all types of blood pressure phenotype and abnormalities with the richness currently achievable only with invasive intra arterial monitoring. Researchers and companies are working on combining technologies like ultrasound, applanation tonometry, and AI algorithms to achieve this goal, pushing the boundaries of wearable health monitoring.¹¹
AI-enabled Personification
As wearables accumulate data over months and years to achieve personalized BP charts, AI models will increasingly be able to move beyond population level BP estimation towards truly individual models. These models can learn the specific relationship between pulse wave characteristics and the blood pressure level of each patient, accounting for the patient’s arterial stiffness, medication regimen, activity patterns and seasonal variation. This personalization is expected to substantially improve long-term accuracy without requiring frequent recalibration against a cuff.
Population Level Surveillance
The aggregation of wearable cardiovascular data at scale has been demonstrated to improve real-time surveillance of cardiovascular risk factors at the population level. As validated wearable BP data becomes more prevalent, epidemiologists and public health officials will gain access to far richer, more continuous BP data from populations than has ever been available, enabling earlier detection of hypertension trends, better evaluation of interventions, and more precise cardiovascular risk stratification.
The Unsolved Problem of Equity
The future of wearable blood pressure monitoring must grapple seriously with health equity. The current devices which are validated are predominantly tested in younger populations with lighter toned skin and healthy normal BP ranges, the very population from which the medical need is lowest.
People with the highest burden of uncontrolled hypertension is on the older adults, people of colour and especially people in low-income settings. Strangely these are the same folks with least representation in validation datasets and they tend to face the greatest barriers to device access and cost. Any future framework for clinical adoption of wearable blood pressure monitoring devices and must address this explicitly.¹²
Conclusion
Wearable technology is changing how hypertension is detected, monitored, and managed. Not by replacing proven clinical tools, but by filling the gaps they cannot cover.
Current evidence supports a measured optimism. Today, wearables function best as screening tools, engagement platforms, and trend trackers rather than standalone diagnostic devices. Regulatory guidelines clearly reinforce this distinction, emphasizing that clinical decisions must still rely on validated cuff-based measurements.
That said, the trajectory is clear. As validation standards evolve, AI-driven personalization improves calibration, and technologies like ultrasound and tonometry mature, wearable blood pressure monitoring is steadily moving toward clinical-grade reliability. When supported by robust evidence rather than marketing claims, continuous monitoring has the potential to transform hypertension care much like continuous glucose monitoring did for diabetes.
Until then, the most effective approach is a combined one: a validated cuff-based device for diagnosis and treatment decisions, paired with wearables for continuous, real-world insights. And at the center of it all remains clinical judgment: interpreting both with context and care.
References
Block RC, Yavarimanesh M, Natarajan K, Carek A, Mousavi A, Chandrasekhar A, Kim CS, Zhu J, Schifitto G, Mestha LK, Inan OT, Hahn JO, Mukkamala R. Conventional pulse transit times as markers of blood pressure changes in humans. Sci Rep. 2020 Oct 2;10(1):16373. doi: 10.1038/s41598-020-73143-8. PMID: 33009445; PMCID: PMC7532447.
Zhou Y, Zhang W, Wang XY, Zhou Y, Li Y, Wang JG. Accuracy of a wearable watch-type oscillometric blood pressure monitor in rest and ambulatory blood pressure measurements. Hypertens Res. 2025 Nov;48(11):2961-2968. doi: 10.1038/s41440-025-02345-2. Epub 2025 Aug 27. PMID: 40866549.
Lee, Y., Park, S., Park, J., Seo, J., & Lee, H.-Y. (2025). Feasibility of watch-based blood pressure monitoring device in Daily Blood Pressure Monitoring. Clinical Hypertension, 31(1). https://doi.org/10.5646/ch.2025.31.e21
Lee, I., & Chang, M. J. (2025). Comparing the accuracy of continuous blood pressure monitoring using wearable cuffless devices with conventional 24-hour ambulatory Blood Pressure Monitoring: A systematic review and meta-analysis. American Journal of Preventive Cardiology, 24, 101342. https://doi.org/10.1016/j.ajpc.2025.101342
Zwahlen M, Pavicic E, Khattab K, Krbanjevic V, Endrass J, Stute P. Non-invasive blood pressure monitoring using wearables for cardiovascular risk assessment: a systematic review. Arch Gynecol Obstet. 2026 Jan 16;313(1):46. doi: 10.1007/s00404-025-08301-2. PMID: 41543583; PMCID: PMC12811358.
2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Hypertension. (n.d.-a). https://doi.org/10.1161/HYP.0000000000000249
Stergiou, G.S., Menti, A., Mariglis, D. et al. The quest for accurate wearable blood pressure monitors. Hypertens Res 49, 1025–1029 (2026). https://doi.org/10.1038/s41440-025-02410-w
Liu S, Cui Y and Chen M (2025) Heart rate variability: a multidimensional perspective from physiological marker to brain-heart axis disorders prediction. Front. Cardiovasc. Med. 12:1630668. doi: 10.3389/fcvm.2025.1630668
Wang BX, Brennand E, Le Page P and Mitchell ARJ (2026) Heart rate variability in cardiovascular disease diagnosis, prognosis and management. Front. Cardiovasc. Med. 12:1680783. doi: 10.3389/fcvm.2025.1680783
Kai, H. The new blood pressure target, a new era: individualized management and precision rooted in clinical decision in JSH2025. Hypertens Res 48, 2781–2783 (2025). https://doi.org/10.1038/s41440-025-02357-y
Min, S., An, J., Lee, J.H. et al. Wearable blood pressure sensors for cardiovascular monitoring and machine learning algorithms for blood pressure estimation. Nat Rev Cardiol 22, 629–648 (2025). https://doi.org/10.1038/s41569-025-01127-0
Cohen, J. B., Byfield, R. L., Hardy, S. T., Juraschek, S. P., Houston Miller, N., Mukkamala, R., Picone, D. S., Thiele, R. H., Yang, E., & Brady, T. M. (2026). Cuffless devices for the measurement of blood pressure: A scientific statement from the American Heart Association. Hypertension, 83(3). https://doi.org/10.1161/hyp.0000000000000254
Comments